Literature DB >> 13436854

The erythromycin group of antibiotics.

L P GARROD.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/effects; ERYTHROMYCIN/effects

Mesh:

Substances:

Year:  1957        PMID: 13436854      PMCID: PMC1961747          DOI: 10.1136/bmj.2.5036.57

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  10 in total

1.  [Not Available].

Authors:  Y CHABBERT
Journal:  Ann Inst Pasteur (Paris)       Date:  1955-10

2.  Development of resistance and cross-resistance in vitro to erythromycin, carbomycin, spiramycin, oleandomycin and streptogramin.

Authors:  M FINLAND; W F JONES; R L NICHOLS
Journal:  Proc Soc Exp Biol Med       Date:  1956-11

3.  Determination of the sensitivity of bacteria to combinations of antibiotics in vitro; discussion of some results, especially with the combination tetracyclin-erythromycin.

Authors:  H J OSKAM
Journal:  Acta Med Scand       Date:  1956-10-15

4.  Antibiotic combinations; antistreptococcal and antistaphylococcal activity of plasma of normal subjects after oral doses of penicillin, oleandomycin and combinations of these antibiotics.

Authors:  M FINLAND; W F JONES
Journal:  N Engl J Med       Date:  1957-01-17       Impact factor: 91.245

5.  [Romicil, a new antibiotic; clinical results in 412 cases].

Authors:  A F ESSELLIER; J KEITH
Journal:  Schweiz Med Wochenschr       Date:  1956-11-17

6.  [Experimental research with oleandomycin].

Authors:  E BOHNI; B FUST; A STUDER; G ZBINDEN
Journal:  Schweiz Med Wochenschr       Date:  1956-11-03

7.  Changes in sensitivity of Micrococcus pyogenes to erythromycin over a period of 2 years.

Authors:  W J MARTIN; D R NICHOLS; W E WELLMAN; J E GERACI
Journal:  Proc Staff Meet Mayo Clin       Date:  1954-06-30

8.  Carbomycin therapy; results of a brief clinical trial, chiefly in patients with pneumonia.

Authors:  M FINLAND; E M PURCELL; S S WRIGHT; B DEL LOVE
Journal:  N Engl J Med       Date:  1953-08-20       Impact factor: 91.245

9.  [Clinical experience with romicil (oleandomycin), a new antibiotic].

Authors:  R HEGGLIN; G KEISER; W SIEGENTHALER
Journal:  Dtsch Med Wochenschr       Date:  1956-12-21       Impact factor: 0.628

10.  Laboratory studies of oleandomycin (matromycin).

Authors:  J E GERACI; G M NEEDHAM
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1956-10
  10 in total
  38 in total

Review 1.  Antibacterial drugs today. I.

Authors:  A P Ball; J A Gray; J M Murdoch
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Thymineless bacteriophage induction in Staphylococcus aureus. II. Specific transduction of constitutive and inducible erythromycin resistance.

Authors:  M Lindberg; L Rudin
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

3.  ANTIBACTERIAL ACTIVITY OF LINCOMYCIN AND PRISTINAMYCIN: A COMPARISON WITH ERYTHROMYCIN.

Authors:  M BARBER; P M WATERWORTH
Journal:  Br Med J       Date:  1964-09-05

4.  Hospital infection yesterday and today.

Authors:  M BARBER
Journal:  J Clin Pathol       Date:  1961-01       Impact factor: 3.411

5.  A NEW TYPE OF ANTIBIOTIC SYNERGY.

Authors:  R H JACKSON
Journal:  Br Med J       Date:  1963-12-14

6.  The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin, and spiramycin.

Authors:  E J LOWBURY; L HURST
Journal:  J Clin Pathol       Date:  1959-03       Impact factor: 3.411

7.  [On the classification of Actinomycetes. 6. Producers of macrolide antibiotics].

Authors:  R HUTTER; W KELLER-SCHIERLEIN; H ZAHNER
Journal:  Arch Mikrobiol       Date:  1961

8.  The comparative toxicity of antibiotics to skin.

Authors:  J C LAWRENCE
Journal:  Br J Pharmacol Chemother       Date:  1959-06

9.  An evaluation of continuous antibiotic therapy in chronic bronchitis.

Authors:  J M MURDOCH; W J LECKIE; J DOWNIE; R H SWAIN; J C GOULD
Journal:  Br Med J       Date:  1959-12-12

10.  In vitro induction of resistance to erythromycin by its metabolite.

Authors:  J Majer
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.